SIMULTANEOUS DETECTION OF MULTIPLE POLYMORPHISMS IN CYP 2 B 6 AND OPMR 1 BY NESTED PCR : A GOOD APPROACH FOR PATIENTS ON METHADONE

Objective: Cytochrome P450 2B6 (CYP2B6) is involved in the metabolism of several therapeutically important drugs and abused intoxicants including methadone. The preferential binding target for methadone is the μ opioid receptor OPRM1. Various SNPs in CYP2B6 and OPRM1 may contribute to clinical outcomes in methadone maintenance therapy. The aim of the present study was to develop a consistent and robust assay to identify such genotypic variants. Methods: We randomly selected patients in the Malay population who were addicted to heroin and had already commenced methadone therapy. We developed a two-step, multiplexed, nested PCR method to simultaneously identify 26 SNPs in CYP2B6 and OPRM1. Three amplicons covering seven regions of interest were amplified in the first PCR step. These amplicons were then used as templates for 11 sets of reactions in the second PCR step. Results: We successfully amplified DNA fragments containing 26 SNPs of interest from the DNA samples provided by patients receiving methadone therapy: C534T, G779A, G13076A, A454G, G24A, G820A, G942A, G31A, G438A, T106C, C440G, T397A, T15708C, T480C, C17T, G794A, A13072G, A76T, A62T, C64T, A136G, C15618T, G691C, G15631T, T802C, and A118G. Conclusion: The PCR-based method was sensitive and specific and is the first nested, allele-specific, multiplexed PCR method reported for the simultaneous detection of all 26 clinically important SNPs of CYP2B6 and OPMR1.

[1]  D. Osselton,et al.  OPRM1 and CYP2B6 Gene Variants as Risk Factors in Methadone‐Related Deaths , 2010, Clinical pharmacology and therapeutics.

[2]  M. Gompels,et al.  CYP2B6 G516T genotyping in a UK cohort of HIV‐positive patients: polymorphism frequency and influence on efavirenz discontinuation , 2009, HIV medicine.

[3]  Shufeng Zhou,et al.  Polymorphism of human cytochrome P450 enzymes and its clinical impact , 2009, Drug metabolism reviews.

[4]  A. Telenti,et al.  Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring? , 2008, European Journal of Clinical Pharmacology.

[5]  M. Ingelman-Sundberg,et al.  Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. , 2007, Pharmacology & therapeutics.

[6]  G. Olsen,et al.  Methadone‐induced respiratory depression in the neonatal guinea pig , 2007, Pediatric pulmonology.

[7]  P. Carrupt,et al.  Stereoselective Block of hERG Channel by (S)‐Methadone and QT Interval Prolongation in CYP2B6 Slow Metabolizers , 2007, Clinical pharmacology and therapeutics.

[8]  R B Altman,et al.  The Pharmacogenetics Research Network: From SNP Discovery to Clinical Drug Response , 2007, Clinical pharmacology and therapeutics.

[9]  Ryan E. Mills,et al.  An initial map of insertion and deletion (INDEL) variation in the human genome. , 2006, Genome research.

[10]  M. Iyo,et al.  Linkage disequilibrium and association with methamphetamine dependence/psychosis of μ-opioid receptor gene polymorphisms , 2006, The Pharmacogenomics Journal.

[11]  Ulrik Stenz Justesen,et al.  Genotyping of CYP2B6 and therapeutic drug monitoring in an HIV-infected patient with high efavirenz plasma concentrations and severe CNS side-effects , 2006, Scandinavian journal of infectious diseases.

[12]  C. Eap,et al.  Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment , 2005, Clinical pharmacology and therapeutics.

[13]  S. Kaasa,et al.  Genetic variability and clinical efficacy of morphine , 2005, Acta anaesthesiologica Scandinavica.

[14]  J. Maxwell,et al.  Deaths of clients in methadone treatment in Texas: 1994-2002. , 2005, Drug and alcohol dependence.

[15]  Robert M. White,et al.  Pharmacogenomics and its applications. , 2005, MLO: medical laboratory observer.

[16]  F. Schifano,et al.  The effects of methadone and its role in fatalities , 2004, Human psychopharmacology.

[17]  E. Kharasch,et al.  Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone , 2004, Clinical pharmacology and therapeutics.

[18]  M. Neville,et al.  Identification of CYP2B6 sequence variants by use of multiplex PCR with allele-specific genotyping. , 2004, Clinical chemistry.

[19]  J. Ott,et al.  Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden , 2004, Molecular Psychiatry.

[20]  C. Chang,et al.  Pharmacogenomics as an aspect of molecular autopsy for forensic pathology/toxicology: does genotyping CYP 2D6 serve as an adjunct for certifying methadone toxicity? , 2003, Journal of forensic sciences.

[21]  C. DeVane,et al.  Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[22]  Richard Schoske,et al.  Multiplex PCR design strategy used for the simultaneous amplification of 10 Y chromosome short tandem repeat (STR) loci , 2003, Analytical and bioanalytical chemistry.

[23]  P. Jannetto,et al.  Pharmacogenomics as molecular autopsy for postmortem forensic toxicology: genotyping cytochrome P450 2D6 for oxycodone cases. , 2002, Journal of analytical toxicology.

[24]  J. Lötsch,et al.  Does the A118G Polymorphism at the &mgr;-opioid Receptor Gene Protect against Morphine-6-Glucuronide Toxicity? , 2002, Anesthesiology.

[25]  K. Wolff.  Characterization of Methadone Overdose: Clinical Considerations and the Scientific Evidence , 2002, Therapeutic drug monitoring.

[26]  Tao Li,et al.  Association analysis of polymorphisms in the mu opioid gene and heroin abuse in Chinese subjects , 2000, Addiction biology.

[27]  A. Somogyi,et al.  Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. , 1999, British journal of clinical pharmacology.

[28]  S. Leal,et al.  Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Long,et al.  μ opioid receptor gene variants: lack of association with alcohol dependence , 1997, Molecular Psychiatry.

[30]  N. Heerema,et al.  Multiplex PCR: critical parameters and step-by-step protocol. , 1997, BioTechniques.

[31]  L. King,et al.  Poisoning-associated Deaths for England and Wales between 1973 and 1980 , 1984, Human toxicology.

[32]  S. Joel,et al.  Clinical response to morphine in cancer patients and genetic variation in candidate genes , 2005, The Pharmacogenomics Journal.

[33]  J. Gerber,et al.  Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. , 2004, Chirality.

[34]  Laurent Galichet,et al.  Clarke's analysis of drugs and poisons in pharmaceuticals, body fluids and postmortem material , 2004 .

[35]  J. Chamberlain,et al.  Optimization of Multiplex PCRs , 1994 .

[36]  M. Eichelbaum,et al.  Clinical Chemistry 53:1 24–33 (2007) Molecular Diagnostics and Genetics MALDI-TOF Mass Spectrometry for Multiplex , 2022 .